Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis

British Medical Journal

Volumn 334, Issue 7588, 2007, Pages 299-302

  Gillies, Clare L ^a   Abrams, Keith R ^a   Lambert, Paul C ^a   Cooper, Nicola J ^a   Sutton, Alex J ^a   Hsu, Ron T ^a   Khunti, Kamlesh ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHINESE DRUG; TETRAHYDROLIPSTATIN; TROGLITAZONE;

CHINESE HERB; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; COUNSELING; DATA SYNTHESIS; GASTROINTESTINAL SYMPTOM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MEDICAL EXPERT; MEDICAL RESEARCH; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; GLUCOSE INTOLERANCE; LIFESTYLE; PUBLISHING; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33847119543     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39063.689375.55     Document Type: Review

References (16)

1. Edelstein SL, Knowler WC, Bain RP. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701-10.
2. Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet Med 2004;21:403-14.
3. Angelo JB, Huang J, Carden D. Diabetes prevention: a review of current literature. Adv Stud Med 2005;5:250-9.
4. Anderson DC Jr. Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 2005;39:102-9.
5. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Schmid CH, et al. Long-term effectiveness of weight-loss interventions in adults with prediabetes: a review. Am J Prev Med 2005;28:126-39.
6. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2005;(2):CD005270.
7. Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 2004;44:406-13.
8. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004;27:247-55.
9. Jadad AR, Moore AR, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
10. De Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA 2001;285:2109-13.
11. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701-10.
12. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
13. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003;26:977-80.
14. Dream Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1608-10.
15. Dream Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
16. Heneghan C, Thompson M, Perera R. Prevention of diabetes. BMJ 2006;333:764-5.